ADME Pharmacogenetics and Its Impact on Drug–Drug Interactions

  • Reinhold Kerb
  • Matthias Schwab


The extent of drug metabolism or drug transport-based pharmacokinetic drug–drug interactions is highly variable between individuals. CYP enzymes such as CYP2B6, CYP2C9, CYP2C19, and CYP2D6 and drug efflux and uptake transporters such as ABCB1 and OAT1B1 display genetic polymorphisms (presence of genetic variants in at least 1% of a population) that may result in altered drug metabolism or transport capacities, respectively. These polymorphisms explain the interindividual variable magnitude of a drug–drug interaction to a significant extent by determining either the substrate susceptibility for interactions or the interaction potential of an inducer or inhibitor. Knowledge of the activity of the enzyme that is responsible for the metabolism of the affected drug or inhibitor can offer vital information when assessing drug interactions. Drug efflux and uptake are increasingly recognized to supplement this information. Nowadays, metabolic and transport statuses are easily accessible by genotyping and are an important prerequisite to fully judge the potential of a drug for drug interactions.


Drug Interaction CYP3A5 Polymorphism SLCO1B1 Gene Erythromycin Breath Test Digoxin Bioavailability 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Abdel-Rahman SM, Gotschall RR, Kauffman RE, Leeder JS and Kearns GL (1999) Investigation of terbinafine as a CYP2D6 inhibitor in vivo. Clin Pharmacol Ther 65: 465–472.CrossRefPubMedGoogle Scholar
  2. Bondolfi G, Eap CB, Bertschy G, Zullino D, Vermeulen A and Baumann P (2002) The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. Pharmacopsychiatry 35:50–56.CrossRefPubMedGoogle Scholar
  3. Bradford LD (2002) CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3:229–243.CrossRefPubMedGoogle Scholar
  4. Bumpus NN, Kent UM and Hollenberg PF (2006) Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms. J Pharmacol Exp Ther 318:345–351.CrossRefPubMedGoogle Scholar
  5. Bumpus NN, Sridar C, Kent UM and Hollenberg PF (2005) The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation. Drug Metab Dispos 33:795–802.CrossRefPubMedGoogle Scholar
  6. Chinn LW and Kroetz DL (2007) ABCB1 pharmacogenetics: progress, pitfalls, and promise. Clin Pharmacol Ther 81:265–269.CrossRefPubMedGoogle Scholar
  7. Cho JY, Yu KS, Jang IJ, Yang BH, Shin SG and Yim DS (2002) Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. Br J Clin Pharmacol 53:393–397.CrossRefPubMedGoogle Scholar
  8. Eap CB, Lessard E, Baumann P, Brawand-Amey M, Yessine M-A, O’Hara G and Turgeon J (2003) Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. Pharmacogenetics 13:39–47.CrossRefPubMedGoogle Scholar
  9. Eichelbaum M, Ingelman-Sundberg M and Evans WE (2006) Pharmacogenomics and individualized drug therapy. Annu Rev Med 57:119–137.CrossRefPubMedGoogle Scholar
  10. Fan L, Wang JC, Jiang F, Tan ZR, Chen Y, Li Q, Zhang W, Wang G, Lei HP, Hu DL, Wang D and Zhou HH (2008a) Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation. Eur J Clin Pharmacol 65:403–409.CrossRefPubMedGoogle Scholar
  11. Fan L, Zhang W, Guo D, Tan ZR, Xu P, Li Q, Liu YZ, Zhang L, He TY, Hu DL, Wang D and Zhou HH (2008b) The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1. Clin Pharmacol Ther 83: 471–476.CrossRefPubMedGoogle Scholar
  12. FDA/CBER (2006) Draft Guidance for Industry: Drug Interaction Studies – Study Design, Data Analysis, and Implications for Dosing and Labeling, in, U.S. Food and Drug Administration.Google Scholar
  13. Flockhart DA (2008) Drug Interactions: Cytochrome P450 Drug Interaction Table, Available at:
  14. Floyd MD, Gervasini G, Masica AL, Mayo G, George AL, Bhat K, Kim RB and Wilkinson GR (2003) Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13:595–606.CrossRefPubMedGoogle Scholar
  15. García-Martín E, Martínez C, Ladero JM and Agúndez JAG (2006) Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther 10:29–40.PubMedGoogle Scholar
  16. Geick A, Eichelbaum M and Burk O (2001) Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276:14581–14587.CrossRefPubMedGoogle Scholar
  17. Geisler T, Schaeffeler E, Dippon J, Winter S, Buse V, Bischofs C, Zuern C, Moerike K, Gawaz M and Schwab M (2008) CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 9: 1251–1259.CrossRefPubMedGoogle Scholar
  18. Gibbs MA, Thummel KE, Shen DD and Kunze KL (1999) Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos 27:180–187.PubMedGoogle Scholar
  19. Hamelin BA, Bouayad A, Methot J, Jobin J, Desgagnes P, Poirier P, Allaire J, Dumesnil J and Turgeon J (2000a) Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin Pharmacol Ther 67:466–477.CrossRefPubMedGoogle Scholar
  20. Hamelin BA, Bouayad A, Méthot J, Jobin J, Desgagnés P, Poirier P, Allaire J, Dumesnil J and Turgeon J (2000b) Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin Pharmacol Ther 67:466–477.CrossRefPubMedGoogle Scholar
  21. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y and Kim RB (2006) Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130:1793–1806.CrossRefPubMedGoogle Scholar
  22. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M and Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97:3473–3478.CrossRefPubMedGoogle Scholar
  23. Hofmann MH, Blievernicht JK, Klein K, Saussele T, Schaeffeler E, Schwab M and Zanger UM (2008) Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther 325:284–292.CrossRefPubMedGoogle Scholar
  24. Hosohata K, Masuda S, Katsura T, Takada Y, Kaido T, Ogura Y, Oike F, Egawa H, Uemoto S and Inui KI (2009) Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients. Drug Metab Dispos 37:821–826.CrossRefPubMedGoogle Scholar
  25. Huang S-M, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, Abraham S, Habet SA, Baweja RK, Burckart GJ, Chung S, Colangelo P, Frucht D, Green MD, Hepp P, Karnaukhova E, Ko H-S, Lee J-I, Marroum PJ, Norden JM, Qiu W, Rahman A, Sobel S, Stifano T, Thummel K, Wei X-X, Yasuda S, Zheng JH, Zhao H and Lesko LJ (2008) New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48:662–670.CrossRefPubMedGoogle Scholar
  26. Huang SM, Temple R, Throckmorton DC and Lesko LJ (2007) Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 81:298–304.CrossRefPubMedGoogle Scholar
  27. Hung CC, Chen CC, Lin CJ and Liou HH (2008) Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics 18:390–402.CrossRefPubMedGoogle Scholar
  28. Ingelman-Sundberg M, Daly AK and Nebert DW (2008) Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee, Available at:
  29. Ingelman-Sundberg M, Sim SC, Gomez A and Rodriguez-Antona C (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496–526.CrossRefPubMedGoogle Scholar
  30. Isoherranen N, Ludington SR, Givens RC, Lamba JK, Pusek SN, Dees EC, Blough DK, Iwanaga K, Hawke RL, Schuetz EG, Watkins PB, Thummel KE and Paine MF (2008) The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation. Drug Metab Dispos 36:146–154.CrossRefPubMedGoogle Scholar
  31. Itagaki F, Homma M, Yuzawa K, Nishimura M, Naito S, Ueda N, Ohkohchi N and Kohda Y (2004) Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations. J Pharm Pharmacol 56:1055–1059.CrossRefPubMedGoogle Scholar
  32. Iwai M, Suzuki H, Ieiri I, Otsubo K and Sugiyama Y (2004) Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics 14:749–757.CrossRefPubMedGoogle Scholar
  33. Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ and Backman JT (2005) Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther 78:388–399.CrossRefPubMedGoogle Scholar
  34. Kalliokoski A, Backman JT, Kurkinen KJ, Neuvonen PJ and Niemi M (2008a) Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism. Clin Pharmacol Ther 84:488–496.CrossRefPubMedGoogle Scholar
  35. Kalliokoski A, Backman JT, Neuvonen PJ and Niemi M (2008b) Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. Pharmacogenetics Genom 18:937–942.CrossRefGoogle Scholar
  36. Kenworthy KE, Bloomer JC, Clarke SE and Houston JB (1999) CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48:716–727.CrossRefPubMedGoogle Scholar
  37. Kerb R (2006) Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 234:4–33.CrossRefPubMedGoogle Scholar
  38. Kerb R, Brinkmann U, Chatskaia N, Gorbunov D, Gorboulev V, Mornhinweg E, Keil A, Eichelbaum M and Koepsell H (2002) Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics 12:591–595.CrossRefPubMedGoogle Scholar
  39. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG and Wilkinson GR (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189–199.CrossRefPubMedGoogle Scholar
  40. Kimchi-Sarfaty C, Oh JM, Kim I-W, Sauna ZE, Calcagno AM, Ambudkar SV and Gottesman MM (2007) A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science (New York, NY) 315:525–528.Google Scholar
  41. Kishi S, Yang W, Boureau B, Morand S, Das S, Chen P, Cook EH, Rosner GL, Schuetz E, Pui C-H and Relling MV (2004) Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 103:67–72.CrossRefPubMedGoogle Scholar
  42. Kongkaew C, Noyce PR and Ashcroft DM (2008) Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother 42:1017–1025.CrossRefPubMedGoogle Scholar
  43. Kumar V, Brundage RC, Oetting WS, Leppik IE and Tracy TS (2008) Differential genotype dependent inhibition of CYP2C9 in humans. Drug Metab Dispos 36:1242–1248.CrossRefPubMedGoogle Scholar
  44. Kumar V, Wahlstrom JL, Rock DA, Warren CJ, Gorman LA and Tracy TS (2006) CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab Dispos 34:1966–1975.CrossRefPubMedGoogle Scholar
  45. Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A, Ohdo S, Ohtani H, Sawada Y, Higuchi S and Otsubo K (2002) Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 72:209–219.CrossRefPubMedGoogle Scholar
  46. Kwara A, Lartey M, Sagoe KW, Xexemeku F, Kenu E, Oliver-Commey J, Boima V, Sagoe A, Boamah I, Greenblatt DJ and Court MH (2008) Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. J Clin Pharmacol 48:1032–1040.CrossRefPubMedGoogle Scholar
  47. Lam YWF, Gaedigk A, Ereshefsky L, Alfaro CL and Simpson J (2002) CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy 22:1001–1006.CrossRefPubMedGoogle Scholar
  48. Lamba J, Strom S, Venkataramanan R, Thummel KE, Lin YS, Liu W, Cheng C, Lamba V, Watkins PB and Schuetz E (2006) MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther 79:325–338.CrossRefPubMedGoogle Scholar
  49. Lan LB, Dalton JT and Schuetz EG (2000) Mdr1 limits CYP3A metabolism in vivo. Mol Pharmacol 58:863–869.PubMedGoogle Scholar
  50. Lang T, Klein K, Fischer J, Nüssler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M and Zanger UM (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399–415.CrossRefPubMedGoogle Scholar
  51. Leabman MK, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, Clark AG, Herskowitz I and Giacomini KM (2002) Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 12:395–405.CrossRefPubMedGoogle Scholar
  52. Lee CR, Goldstein JA and Pieper JA (2002) Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12:251–263.CrossRefPubMedGoogle Scholar
  53. Lessard E, Yessine MA, Hamelin BA, Gauvin C, Labbé L, O‘Hara G, LeBlanc J and Turgeon J (2001) Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans. J Clin Psychopharmacol 21:175–184.CrossRefPubMedGoogle Scholar
  54. Lim KS, Cho JY, Jang IJ, Kim BH, Kim J, Jeon JY, Tae YM, Yi S, Eum S, Shin SG and Yu KS (2008) Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects. Br J Clin Pharmacol 66:660–666.PubMedGoogle Scholar
  55. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M and Collins R (2008) SLCO1B1 variants and statin-induced myopathy – a genomewide study. N Engl J Med 359:789–799.CrossRefPubMedGoogle Scholar
  56. Llerena A, Berecz R, de la Rubia A, Fernández-Salguero P and Dorado P (2001) Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes. Ther Drug Monit 23:616–620.CrossRefPubMedGoogle Scholar
  57. Ma Q and Lu AYH (2007) CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies. Drug Metab Dispos 35:1009–1016.CrossRefPubMedGoogle Scholar
  58. McCune JS, Hawke RL, LeCluyse EL, Gillenwater HH, Hamilton G, Ritchie J and Lindley C (2000) In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther 68:356–366.CrossRefPubMedGoogle Scholar
  59. Meyer UA (2004) Pharmacogenetics – five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 5:669–676.CrossRefPubMedGoogle Scholar
  60. Mikus G, Schowel V, Drzewinska M, Rengelshausen J, Ding R, Riedel KD, Burhenne J, Weiss J, Thomsen T and Haefeli WE (2006) Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther 80:126–135.CrossRefPubMedGoogle Scholar
  61. Miura M, Inoue K, Kagaya H, Satoh S, Tada H, Sagae Y, Habuchi T and Suzuki T (2007) Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. Biopharm Drug Dispos 28:167–175.CrossRefPubMedGoogle Scholar
  62. Neuvonen PJ, Niemi M and Backman JT (2006) Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80:565–581.CrossRefPubMedGoogle Scholar
  63. Niemi M (2007) Role of OATP transporters in the disposition of drugs. Pharmacogenomics 8:787–802.CrossRefPubMedGoogle Scholar
  64. Niemi M, Kivisto KT, Diczfalusy U, Bodin K, Bertilsson L, Fromm MF and Eichelbaum M (2006) Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin. Pharmacogenet Genomics 16:565–568.CrossRefPubMedGoogle Scholar
  65. Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb R, Schwab M, Neuvonen PJ, Eichelbaum M and Kivistö KT (2004) High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14:429–440.CrossRefPubMedGoogle Scholar
  66. Nies AT (2007) The role of membrane transporters in drug delivery to brain tumors. Cancer Lett 254:11–29.CrossRefPubMedGoogle Scholar
  67. Nies AT, Schwab M and Keppler D (2008) Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs. Expert Opin Drug Metab Toxicol 4:545–568.CrossRefPubMedGoogle Scholar
  68. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, Urae A, Higuchi S, Otsubo K and Sugiyama Y (2003) Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73:554–565.CrossRefPubMedGoogle Scholar
  69. Roberts PJ, Rollins KD, Kashuba AD, Paine MF, Nelsen AC, Williams EE, Moran C, Lamba JK, Schuetz EG and Hawke RL (2008) The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans. Drug Metab Dispos 36:1465–1469.CrossRefPubMedGoogle Scholar
  70. Schwab M, Schaeffeler E, Klotz U and Treiber G (2004) CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin Pharmacol Ther 76:201–209.CrossRefPubMedGoogle Scholar
  71. Schwarz UI, Hanso H, Oertel R, Miehlke S, Kuhlisch E, Glaeser H, Hitzl M, Dresser GK, Kim RB and Kirch W (2007) Induction of intestinal P-glycoprotein by St John’s wort reduces the oral bioavailability of talinolol. Clin Pharmacol Ther 81:669–678.CrossRefPubMedGoogle Scholar
  72. Seithel A, Glaeser H, Fromm MF and König J (2008) The functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members. Expert Opin Drug Metab Toxicol 4:51–64.CrossRefPubMedGoogle Scholar
  73. Shimizu T, Ochiai H, Asell F, Shimizu H, Saitoh R, Hama Y, Katada J, Hashimoto M, Matsui H, Taki K, Kaminuma T, Yamamoto M, Aida Y, Ohashi A and Ozawa N (2003) Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab Pharmacokinet 18:48–70.CrossRefPubMedGoogle Scholar
  74. Shon JH, Yoon YR, Hong WS, Nguyen PM, Lee SS, Choi YG, Cha IJ and Shin JG (2005) Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Clin Pharmacol Ther 78:191–201.CrossRefPubMedGoogle Scholar
  75. Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP, Sheardown SA, Yue L, Burchard EG, Brett CM and Giacomini KM (2008) Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 83:273–280.CrossRefPubMedGoogle Scholar
  76. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, Brett CM and Giacomini KM (2007) Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 117:1422–1431.CrossRefPubMedGoogle Scholar
  77. Sim SC, Risinger C, Dahl M-L, Aklillu E, Christensen M, Bertilsson L and Ingelman-Sundberg M (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103–113.CrossRefPubMedGoogle Scholar
  78. Skarke C, Jarrar M, Schmidt H, Kauert G, Langer M, Geisslinger G and Lotsch J (2003) Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics 13:651–660.CrossRefPubMedGoogle Scholar
  79. Spina E, Santoro V and D‘Arrigo C (2008) Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 30:1206–1227.CrossRefPubMedGoogle Scholar
  80. Stresser DM, Blanchard AP, Turner SD, Erve JC, Dandeneau AA, Miller VP and Crespi CL (2000) Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 28:1440–1448.PubMedGoogle Scholar
  81. Talakad JC, Kumar S and Halpert JR (2009) Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs. Drug Metab Dispos 37:644–650.CrossRefPubMedGoogle Scholar
  82. Tirona RG, Leake BF, Merino G and Kim RB (2001) Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 276:35669–35675.CrossRefPubMedGoogle Scholar
  83. Tirona RG, Leake BF, Wolkoff AW and Kim RB (2003) Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304:223–228.CrossRefPubMedGoogle Scholar
  84. Uno T, Sugimoto K, Sugawara K and Tateishi T (2008) The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. Ther Drug Monit 30:276–281.CrossRefPubMedGoogle Scholar
  85. Verstuyft C, Strabach S, El-Morabet H, Kerb R, Brinkmann U, Dubert L, Jaillon P, Funck-Brentano C, Trugnan G and Becquemont L (2003) Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. Clin Pharmacol Ther 73:51–60.CrossRefPubMedGoogle Scholar
  86. Vesell ES and Page JG (1969) Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man. J Clin Invest 48:2202–2209.CrossRefPubMedGoogle Scholar
  87. Wang RW, Newton DJ, Liu N, Atkins WM and Lu AY (2000) Human cytochrome P-450 3A4: in vitro drug–drug interaction patterns are substrate-dependent. Drug Metab Dispos 28:360–366.PubMedGoogle Scholar
  88. Wang ZJ, Yin OQ, Tomlinson B and Chow MS (2008) OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics 18:637–645.CrossRefPubMedGoogle Scholar
  89. Wang LS, Zhu B, Abd El-Aty AM, Zhou G, Li Z, Wu J, Chen GL, Liu J, Tang ZR, An W, Li Q, Wang D and Zhou HH (2004) The influence of St John’s Wort on CYP2C19 activity with respect to genotype. J Clin Pharmacol 44:577–581.CrossRefPubMedGoogle Scholar
  90. Westlind-Johnsson A, Hermann R, Huennemeyer A, Hauns B, Lahu G, Nassr N, Zech K, Ingelman-Sundberg M and von Richter O (2006) Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity. Clin Pharmacol Ther 79:339–349.CrossRefPubMedGoogle Scholar
  91. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD and Wrighton SA (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 30:883–891.CrossRefPubMedGoogle Scholar
  92. Wojnowski L (2004) Genetics of the variable expression of CYP3A in humans. Ther Drug Monit 26:192–199.CrossRefPubMedGoogle Scholar
  93. Yang LJ, Fan L, Liu ZQ, Mao YM, Guo D, Liu LH, Tan ZR, Peng L, Han CT, Hu DL, Wang D and Zhou HH (2009) Effects of allicin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes. Eur J Clin Pharmacol 65:601–608.CrossRefPubMedGoogle Scholar
  94. Yasui-Furukori N, Saito M, Uno T, Takahata T, Sugawara K and Tateishi T (2004a) Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J Clin Pharmacol 44:1223–1229.CrossRefPubMedGoogle Scholar
  95. Yasui-Furukori N, Takahata T, Nakagami T, Yoshiya G, Inoue Y, Kaneko S and Tateishi T (2004b) Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br J Clin Pharmacol 57:487–494.CrossRefPubMedGoogle Scholar
  96. Yu K-S, Cho J-Y, Jang I-J, Hong K-S, Chung J-Y, Kim J-R, Lim H-S, Oh D-S, Yi S-Y, Liu K-H, Shin J-G and Shin S-G (2004) Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin Pharmacol Ther 76:104–112.CrossRefPubMedGoogle Scholar
  97. Yu KS, Yim DS, Cho JY, Park SS, Park JY, Lee KH, Jang IJ, Yi SY, Bae KS and Shin SG (2001) Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther 69:266–273.CrossRefPubMedGoogle Scholar
  98. Zaïr ZM, Eloranta JJ, Stieger B and Kullak-Ublick GA (2008) Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney. Pharmacogenomics 9:597–624.CrossRefPubMedGoogle Scholar
  99. Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann MH and Schwab M (2007) Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 8:743–759.CrossRefPubMedGoogle Scholar
  100. Zanger U, Turpeinen M, Klein K and Schwab M (2008) Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 392:1093–1108.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Dr Margarete Fischer-Bosch Institute of Clinical PharmacologyUniversity of TübingenStuttgartGermany

Personalised recommendations